Chronic Kidney Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | GNI Group Ltd, iBio Inc, IC-MedTech Inc, Ipsen SA, Isarna Therapeutics, KBP BioSciences and Others

June 02 21:50 2021
Chronic Kidney Disease Pipeline: Emerging Therapies and Key pharma players involved by DelveInsight | GNI Group Ltd, iBio Inc, IC-MedTech Inc, Ipsen SA, Isarna Therapeutics, KBP BioSciences and Others

Chronic Kidney Disease Pipeline

Chronic Kidney Disease is a condition in which the kidneys are damaged and cannot filter blood as well as they should. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke. Some other health consequences of Chronic Kidney Disease include:

  • Anemia or low number of red blood cells
  • Increased occurrence of infections
  • Low calcium levels, high potassium levels, and high phosphorus levels in the blood
  • Loss of appetite or eating less
  • Depression or lower quality of life

 

DelveInsight’s, “Chronic Kidney Disease Pipeline Insights, 2021,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight

 

Some of Chronic Kidney Disease Companies are:

  • AdAlta Ltd
  • Allena Pharmaceuticals Inc
  • apceth Biopharma GmbH
  • Arch Biopartners Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bayer AG
  • BiOrion Technologies BV
  • Boehringer Ingelheim GmbH
  • Boryung Pharmaceutical Co Ltd
  • Celgene Corp
  • Certa Therapeutics Pty Ltd
  • Conatus Pharmaceuticals Inc
  • Corvidia Therapeutics Inc
  • DiaMedica Therapeutics Inc
  • Dimerix Bioscience Pty Ltd
  • DiscoveryBiomed Inc
  • DURECT Corp
  • Epigen Biosciences Inc
  • Galectin Therapeutics Inc
  • GenKyoTex SA
  • GNI Group Ltd
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight

 

DelveInsight’s Chronic Kidney Disease report covers around 50+ products under different phases of clinical development like

  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of Chronic Kidney Disease Therapies are:

  • AZD5718
  • MEDI8367
  • efepoetin alfa
  • Verinurad
  • Empagliflozin
  • DDO-3055
  • KBP-5074
  • Doxercalciferol
  • TRC101
  • Pegol-Sihematide
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight

 

Current Chronic Kidney Disease Treatment Scenario and Chronic Kidney Disease Emerging Therapies:

  • How many companies are developing Chronic Kidney Disease drugs?
  • How many Chronic Kidney Disease drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Kidney Disease?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Kidney Disease therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Kidney Disease and their status?
  • What are the key designations that have been granted to the emerging drugs?

 

Table of Contents:

Introduction

Executive Summary

Chronic Kidney Disease: Overview

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

Chronic Kidney Disease – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Chronic Kidney Disease companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Chronic Kidney Disease Collaboration Deals

Late Stage Products (Phase III)

• Comparative Analysis

Pegol-Sihematide: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

AZD5718: AstraZeneca

KBP-5074: KBP Biosciences

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Chronic Kidney Disease Key Companies

Chronic Kidney Disease Key Products

Chronic Kidney Disease- Unmet Needs

Chronic Kidney Disease- Market Drivers and Barriers

Chronic Kidney Disease- Future Perspectives and Conclusion

Chronic Kidney Disease Analyst Views

Chronic Kidney Disease Key Companies

Appendix

Request for Detailed TOC: https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight


Warning: count(): Parameter must be an array or an object that implements Countable in /home/indoreonlinejour/haryanadaily.in/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7